![Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial | Reproductive Health | Full Text Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial | Reproductive Health | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12978-017-0292-7/MediaObjects/12978_2017_292_Fig1_HTML.gif)
Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial | Reproductive Health | Full Text
![IJMS | Free Full-Text | 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? IJMS | Free Full-Text | 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?](https://www.mdpi.com/ijms/ijms-23-03431/article_deploy/html/images/ijms-23-03431-g001.png)
IJMS | Free Full-Text | 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?
![Genital herpes and pregnancy: Understanding the risks | Your Pregnancy Matters | UT Southwestern Medical Center Genital herpes and pregnancy: Understanding the risks | Your Pregnancy Matters | UT Southwestern Medical Center](https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/original_images/GettyImages-926657584.jpg)